Aspirin Resistance and Compliance with Therapy

Cardiovascular Therapeutics

Volumn 29, Issue 5, 2011, Pages 301-307

  Dawson, Jesse ^a   Quinn, Terry ^a   Rafferty, Mark ^a   Higgins, Peter ^a   Ray, Gautamanda ^b   Lees, Kennedy R ^a   Walters, Matthew R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ROYAL ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

Antiplatelet; Aspirin; Compliance; Resistance; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; DRUG METABOLITE;

AGED; ANALYZER; ARTICLE; BLOOD CLOTTING PARAMETERS; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG URINE LEVEL; FEMALE; HEART MUSCLE ISCHEMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INGESTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; THROMBOCYTE FUNCTION;

AGED; AGED, 80 AND OVER; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SCOTLAND; STROKE; TREATMENT FAILURE;

EID: 80053165917     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00188.x     Document Type: Article

References (32)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
2. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet 2006;367:1665-1673.
3. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee. Lancet 1996;348:1329-1339.
4. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717.
5. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ 2008;336:195-198.
6. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-2336.
7. Snoep JD, Hovens MM, Eikenboom JC, Van Der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis. Arch Intern Med 2007;167:1593-1599.
8. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003;250:63-66.
9. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397-403.
10. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005;95:973-975.
11. Wang YJ, Wu D, Wang YL, Ma RH, Wang CX, Zhao WK. A survey on adherence to secondary ischemic stroke prevention. Neurol Res 2006;28:16-20.
12. De Schryver ELLM, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol 2005;252:1316-1321.
13. Newby LK, LaPointe NMA, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006;113:203-212.
14. Eagle KA, Kline-Rogers E, Goodman SG. Adherence to evidence-based therapies after discharge for acute coronary syndromes: An ongoing prospective, observational study. Am J Med 2004;117:73-81.
15. Sud A, Kline-Rogers EM, Eagle KA, et al. Adherence to medications by patients after acute coronary syndromes. Ann Pharmacother 2005;39:1792-1797.
16. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer (PFA-100). Semin Thromb Hemost 1995;21:106-112.
17. Harrison P. Platelet function analysis. Blood Rev 2005;19:111-123.
18. Wang JC, Aucoin-Barry D, Manuelian D, et al. Incidence of aspirin nonresponsiveness using the Ultegra rapid platelet function assay-ASA. Am J Cardiol 2003;92:1492-1494.
19. Malinin A, Spergling M, Muhlestein B, Steinhubl S, Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004;15:295-301.
20. Buskin JN, Upton RA, Williams RL. Improved liquid-chromatography of aspirin, salicylate, and salicyluric acid in plasma, with a modification for determining aspirin metabolites in urine. Clin Chem 1982;28:1200-1203.
21. Baxter GJ, Lawrence JR, Graham AB, Wiles D, Paterson JR. Identification and determination of salicylic acid and salicyluric acid in urine of people not taking salicylate drugs. Ann Clin Biochem 2002;39:50-55.
22. Dorsch MP, Lee JS, Lynch DR, et al. Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann Pharmacother 2007;41:737-741.
23. Williams MS, Kickler TS, Vaidya D, Ng'alla LS, Bush DE. Evaluation of platelet function in aspirin treated patients with CAD. J Thromb Thrombolysis 2006;21:241-247.
24. Tarjan J, Salamon A, Jager R, et al. The rate of acetylsalicylic acid non-respondents among patients hospitalized for acute coronary disease, previously undergoing secondary salicylic acid prophylaxis. Orv Hetil 1999;140:2339-2343.
25. Dalen JE. Aspirin resistance: Is it real? Is it clinically significant? Am J Med 2007;120:1-4.
26. McCabe DJH, Harrison P, Mackie IJ, et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 2005;16:269-280.
27. Berrouschot J, Schwetlick B, von Twickel G, et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006;113:31-35.
28. McCabe D, Harrison P, Mackie I, Sidhu P, Machin S, Brown M. Measurement of aspirin responsiveness in ischaemic stroke and TIA using the PFA-100. Stroke 2000;31:2797.
29. Navarro JC, Lao AY, Yumul MP, Araullo LC, Lokin JK, Baroque AC. Aspirin resistance among patients with recurrent non-cardiogenic stroke detected by rapid platelet function analyser. Neurol Asia 2007;12:89-95.
30. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965.
31. Lee PY, Chen WH, Ng W, Cheng X, Kwok JY, Tse HF, Lau CP. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005;118:723-727.
32. Stejskal D, Vaclavik J, Lacnak B, Proskova J. Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur J Intern Med 2006;17:349-354.